NCI Research Specialist (Clinician Scientist) Award

NCI 研究专家（临床科学家）奖

• 批准号: 10569403
• 负责人: Karyn A Goodman
• 金额: $ 9.11万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-17 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569403
• 关键词: Address; Adjuvant; American College of Radiology Imaging Network; Award; Cancer and Leukemia Group B; Catchment Area; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Colorado; Development; Eastern Cooperative Oncology Group; Equity; Faculty; Fostering; Funding; Funding Mechanisms; Goals; Growth; Health system; Hospitals; Institution; Investigational Therapies; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of pancreas; Minority Recruitment; NCI-Designated Cancer Center; National Clinical Trials Network; New York City; Oncology; Patients; Play; Positioning Attribute; Positron-Emission Tomography; Principal Investigator; Radiation Oncology; Radiation Therapy Oncology Group; Research; Resectable; Role; Scientist; Services; Specialist; The University of Colorado Cancer Center; Work; cancer care; cancer clinical trial; chemoradiation; drug development; fighting; gastrointestinal; improved; investigator-initiated trial; patient population; phase II trial; phase III trial; programs

ABSTRACT Dr. Karyn Goodman plays a critical role in Tisch Cancer Institute’s (TCI) cancer clinical trial program and in supporting NCI-funded clinical trials. She has demonstrated a long-term commitment to this work through her previous role as Associate Director (AD) of Clinical Research for 3 years at the University of Colorado Cancer Center. In the same role in the TCI, Dr. Goodman has been able to further expand on the work she was doing in Colorado and has focused on five major goals: 1) to expand access to clinical trials across the Mount Sinai Health System (MSHS); 2) to increase the numbers of NCI-sponsored trials performed across the MSHS; 3) to address the need for more oversight and integration of clinical trial services provided across the MSHS; 4) to support junior faculty to develop investigator-initiated trials (IITs) and present concepts to the Experimental Therapeutic Clinical Trials Network (ETCTN) for potential support; and, 5) to increase minority recruitment to TCI clinical trials. Institutionally, she has been the local PI of numerous National Clinical Trials Network (NCTN) studies at several NCI-designated cancer centers and is currently the Mount Sinai PI for one ECOG/ACRIN trial and one ETCTN trial and serves as the PI for the Early Drug Development Opportunity Program (EDDOP) at Mount Sinai. In addition, she is a national leader in the NCTN both through her involvement in the GI committees of the Alliance for Clinical Trials in Oncology and the NRG Oncology, as well as her role as the co-chair of the NCI Gastrointestinal Steering Committee. She has nicely bridged the work she has done nationally with her institutional AD of Clinical Research position. She brings her expertise in clinical trial development and oversight which she gained as the National Study Chair of the CALGB/Alliance 80803, a Phase II trial that evaluated PET-directed therapy for esophageal cancer, and the National Radiation Oncology Principal Investigator of the RTOG/NRG 0848, a large Phase III trial investigating the role of adjuvant chemoradiation in resectable pancreas cancer. Her overarching goal as a senior leader in the TCI is to support the development of both IITs and NCI-funded cooperative group clinical trials that will further advance the fight against cancer. The R50 funding mechanism will undoubtedly help foster her ability to expand NCI-funded oncology clinical research at Mount Sinai Hospital and expand access to these trials across the MSHS. Dr. Goodman is uniquely positioned for this award with both her institutional and national service focused on developing and supporting cancer clinical research.

抽象的 Karyn Goodman 博士在 Tisch 癌症研究所 (TCI) 的癌症临床试验项目中发挥着关键作用， 支持 NCI 资助的临床试验。她表现出了对这项工作的长期承诺 此前，她曾在伦敦大学临床研究副主任 (AD) 工作了 3 年。 科罗拉多癌症中心。 Goodman 博士在 TCI 中担任同样的角色，能够进一步扩展 她在科罗拉多州所做的工作重点关注五个主要目标：1）扩大临床治疗的机会 西奈山卫生系统 (MSHS) 的试验； 2）增加NCI资助的试验数量 跨 MSHS 执行； 3) 满足对临床试验进行更多监督和整合的需求 通过 MSHS 提供的服务； 4）支持初级教师开展研究者发起的试验 (IIT) 并向实验性治疗临床试验网络 (ETCTN) 展示潜在的概念 支持; 5) 增加 TCI 临床试验的少数招募。从制度上来说，她一直是 多项国家临床试验网络 (NCTN) 多个 NCI 指定癌症研究的当地 PI 中心，目前是一项 ECOG/ACRIN 试验和一项 ETCTN 试验的西奈山 PI，并担任 西奈山早期药物开发机会计划 (EDDOP) 的 PI。除此之外，她还是 通过参与联盟的地理标志委员会，她成为 NCTN 的国家领导人 肿瘤学和 NRG 肿瘤学的临床试验，以及她作为 NCI 联合主席的角色 胃肠道指导委员会。她很好地将她在全国范围内所做的工作与她联系起来 临床研究职位机构AD。她带来了临床试验开发方面的专业知识和 她作为 CALGB/Alliance 80803 的国家研究主席获得了监督，这是一项 II 期试验， 评估了食管癌的 PET 定向治疗，以及国家放射肿瘤学负责人 RTOG/NRG 0848 的研究员，这是一项大型 III 期试验，调查佐剂的作用 可切除胰腺癌的放化疗。作为 TCI 高级领导者，她的总体目标是 支持 IIT 和 NCI 资助的合作团体临床试验的发展，这将进一步 推进与癌症的斗争。 R50资助机制无疑将有助于培养她的能力 扩大 NCI 资助的西奈山医院肿瘤学临床研究，并扩大这些试验的参与范围 跨越 MSHS。古德曼博士因其机构和能力而获得该奖项的独特地位 国家服务重点是发展和支持癌症临床研究。